Nauta Irene H, Nijenhuis Dennis N L M, Ganzevles Sonja H, Raaff Pamela I, Kloosterman Jan, Bloemena Elisabeth, Brakenhoff Ruud H, Leemans C René, van de Ven Rieneke
Department of Otolaryngology/Head and Neck Surgery, Vrije Universiteit, Amsterdam UMC, Boelelaan 1117, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
Cancer Biology and Immunology, Cancer Center Amsterdam (CCA), 1081 HV Amsterdam, The Netherlands.
Cancers (Basel). 2025 Jan 1;17(1):113. doi: 10.3390/cancers17010113.
BACKGROUND/OBJECTIVES: Most studies on the interaction between the immune system and cancer focus on T-cells, whereas studies on tumor-infiltrating B-lymphocytes (TIL-Bs) are still underrepresented. The aim of this study was to assess the prognostic impact of TIL-Bs in early- and advanced-stage oral cavity squamous cell carcinoma (OCSCC).
In total, 222 OCSCCs were studied. Consecutive sections were stained for CD45 and CD19. OCSCCs were categorized as either "TIL-B-rich" or "TIL-B-poor", and the survival of both groups was analyzed. Similar analyses were performed for CD45+ TILs and the CD19/CD45 ratio. Matched subgroups of twelve TIL-B-rich and TIL-B-poor tumors were stained for CD3 and CD8 to determine differences in T-cell infiltration, and further spatial interaction between T- and B-cells was evaluated in six samples.
Five-year OS was 75.0% for TIL-B-rich and 54.2% for TIL-B-poor OCSCCs ( < 0.001). The survival benefit of TIL-B-rich OCSCCs remained significant after correction for the histopathological characteristics ( = 0.033). While for early-stage tumors, TIL-B richness benefited OS independent of demographic-, clinical, or histopathological features, for advanced-stage disease, this was not the case, although a clear benefit of a TIL-B-rich status was observed, specifically up until 36 months after diagnosis. TIL-B-rich tumors contained more CD3+ TILs ( = 0.007), but not CD8+ TILs. Spatial characterization suggested that TIL-Bs mostly co-localized with CD3+CD8- TILs and that this interaction was increased in TIL-B-rich OCSCC.
The presence of TIL-Bs is associated with a more favorable prognosis in OCSCC, in particular for early-stage disease.
背景/目的：大多数关于免疫系统与癌症相互作用的研究集中于T细胞，而对肿瘤浸润性B淋巴细胞（TIL-B）的研究仍较少。本研究旨在评估TIL-B在早期和晚期口腔鳞状细胞癌（OCSCC）中的预后影响。
共研究了222例OCSCC。连续切片进行CD45和CD19染色。OCSCC被分为“TIL-B丰富”或“TIL-B缺乏”两类，并分析两组的生存率。对CD45+ TIL和CD19/CD45比值进行了类似分析。选取12例TIL-B丰富和TIL-B缺乏肿瘤的配对亚组进行CD3和CD8染色，以确定T细胞浸润的差异，并在6个样本中评估T细胞和B细胞之间进一步的空间相互作用。
TIL-B丰富的OCSCC患者5年总生存率为75.0%，TIL-B缺乏的为54.2%（P<0.001）。校正组织病理学特征后，TIL-B丰富的OCSCC的生存获益仍然显著（P=0.033）。对于早期肿瘤，TIL-B丰富独立于人口统计学、临床或组织病理学特征对总生存有益，而对于晚期疾病则不然，尽管观察到TIL-B丰富状态有明显益处，特别是在诊断后36个月内。TIL-B丰富的肿瘤含有更多的CD3+ TIL（P=0.007），但CD8+ TIL没有增多。空间特征表明，TIL-B大多与CD3+CD8-TIL共定位，且这种相互作用在TIL-B丰富的OCSCC中增强。
TIL-B的存在与OCSCC更有利的预后相关，特别是对于早期疾病。
